⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16821992 | 0.82 | TAAR1 (0.50) | — | |
| SCHEMBL8048996 | 0.82 | LOXL2 (0.46) | — | |
| SCHEMBL3643700 | 0.78 | — | — | |
| SCHEMBL1620286 | 0.76 | — | — | |
| SCHEMBL7221559 | 0.76 | — | — | |
| SCHEMBL805059 | 0.76 | — | — | |
| SCHEMBL9645885 | 0.76 | — | — | |
| SCHEMBL693319 | 0.76 | — | — | |
| SCHEMBL21909723 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL2009943 | 0.76 | HCAR2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| EP-4626891-A1 | FUSED PYRIMIDINES AS MASP-2 INHIBITORS | Omeros Corporation (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4050005-B1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| US-20240228499-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024118840-A1 | FUSED PYRIMIDINES AS MASP-2 INHIBITORS | OMEROS CORPORATION (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024029877-A1 | NOVEL PURINE DERIVATIVE COMPOUNDS AS A3 ADENOSINE RECEPTOR AGONISTS | 주식회사 넥스트젠바이오사이언스 | 2024-02-08 | — | — | WO | disclosed |
| EP-4240736-A1 | PPAR GAMMA MODULATORS AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2023-09-13 | — | — | EP | disclosed |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| EP-4050005-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2022-08-31 | — | — | EP | disclosed |
| WO-2022099144-A1 | ΡΡΑRγ MODULATORS AND METHODS OF USE | Eisai R&D Mangement Co., Ltd. (JP) | 2022-05-12 | — | — | WO | disclosed |
| US-20090281325-A1 | METHOD FOR SELECTIVELY PRODUCING PRIMARY AMINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| CN-101370765-A | Method for selectively producing primary amine | SUMITOMO CHEMICAL CO (JP) | 2009-02-18 | — | — | CN | disclosed |
| EP-1961733-A1 | METHOD FOR SELECTIVELY PRODUCING PRIMARY AMINE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-08-27 | — | — | EP | disclosed |
| US-20070225282-A1 | PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
| US-20070225282-A1 | PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
| US-20070225282-A1 | PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
| WO-2007109459-A2 | PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN | JANSSEN PHARMACEUTICA, NV (BE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109459-A2 | PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN | JANSSEN PHARMACEUTICA, NV (BE) | 2007-09-27 | — | — | WO | disclosed |
| CN-1317265-C | Cyanoacrylate derivatives and their preparation method and biological activity | UNIV GUIZHOU (CN) | 2007-05-23 | — | — | CN | disclosed |
| CN-1603307-A | Cyanoacrylate derivatives and their preparation method and biological activity | UNIV GUIZHOU (CN) | 2005-04-06 | — | — | CN | disclosed |